1. In Vivo

Sorin CRM: Cracking the US Market

Sorin's history of important technology breakthroughs has long been one of the best kept secrets in the cardiac rhythm management market. The company is now restructuring to focus on CRM, particularly in the US, and challenge the major players on their home turf.

While large-scale consolidation has occurred in several major medical device markets, it has generally tended to serve different purposes in each industry segment. In orthopedics, a handful of large deals, most notably Stryker’s purchase of Howmedica and Johnson & Johnson’s acquisition of DePuy, took a highly fragmented market (in terms of market share) and created a much more concentrated one, connecting commercial success to critical mass. In interventional cardiology, on the other hand, consolidation has tended to give companies wishing to build bigger franchises the technology and market footprint they needed—think of Boston Scientific’s acquisition of SciMed LifeSystems or Medtronic’s purchase of AVE.

No industry sector more clearly exhibits the sustained dynamics of consolidation than the cardiac rhythm management (CRM) market. But consolidation...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo

Pharma’s Space Trails Entering Transformative Era

 
• By Anju Ghangurde

Merck and Lilly are among the leading pharma players using space-based research to power drug development. From reusable satellites to process drugs in low earth orbit to biomanufacturing labs experts discuss R&D opportunities in the starry canvas above.

Surgical Robotics CEOs Talk Metrics For Success, Valuations And Competition

 
• By Marion Webb

Leaders of robotic systems companies Distalmotion, Neocis and Noah Medical discussed success metrics, competition and funding. Institutional investors are focusing on utilization, procedure rates and a clear path to profitability as the IPO window reopens, BTIG analyst Ryan Zimmerman said.

Podcast: Astellas SVP On Doubling Down On Gene Therapy Despite Industry Headwinds

 
• By David Wild

Richard Wilson, SVP and primary focus lead for genetic regulation at Astellas, talks with In Vivo about the company's commitment to AAV as a gene therapy delivery vehicle, recent company investments and the regulatory environment under Trump's FDA.